.jpg)
Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer, Gilead Sciences’ Trodelvy has notched a much-needed win.
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer, Gilead Sciences’ Trodelvy has notched a much-needed win.
